首页> 外文期刊>Molecular cancer research: MCR >Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer.
【24h】

Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer.

机译:人类前列腺肿瘤原代培养的上皮限制基因概况:一种预测前列腺癌临床行为的分子方法。

获取原文
获取原文并翻译 | 示例
           

摘要

The histopathologic and molecular heterogeneity of prostate cancer and the limited availability of human tumor tissue make unraveling the mechanisms of prostate carcinogenesis a challenging task. Our goal was to develop an ex vivo model that could be reliably used to define a prognostic signature based on gene expression profiling of cell cultures that maintained the tumor phenotype. To this end, we derived epithelial cultures from tissue explanted from 59 patients undergoing radical prostatectomy or cistoprostatectomy because of prostate benign hyperplasia/prostate cancer or bladder carcinoma. Patient selection criteria were absence of hormonal neoadjuvant treatment before surgery and diagnosis of clinically localized disease. Using this unique experimental material, we analyzed expression of 22,500 transcripts on the Affymetrix Human U133A GeneChip platform (Affymetrix, Inc., High Wycombe, United Kingdom). Cultures from normal/hyperplastic tissues with a prevalent luminal phenotype and from normal prostate epithelial tissue with basal phenotype (PrEC) served as controls. We have established a large number of prostate primary cultures highly enriched in the secretory phenotype. From them, we derived an epithelial-restricted transcriptional signature that (a) differentiated normal from tumor cells and (b) clearly separated cancer-derived lines into two distinct groups, which correlated with indolent or aggressive clinical behavior of the disease. Our findings provide (a) a method to expand human primary prostate carcinoma cells with a luminal phenotype, (b) a powerful experimental model to study primary prostate cancer biology, and (c) a novel means to characterize these tumors from a molecular genetic standpoint for prognostic and/or predictive purposes.
机译:前列腺癌的组织病理学和分子异质性以及人类肿瘤组织的有限可获得性使弄清前列腺癌发生的机理成为一项艰巨的任务。我们的目标是开发一种体外模型,该模型可以可靠地用于基于维持肿瘤表型的细胞培养物的基因表达谱来定义预后标志。为此,我们从59例因前列腺良性增生/前列腺癌或膀胱癌而接受根治性前列腺切除术或顺式前列腺切除术的患者移植的组织中提取了上皮培养物。患者的选择标准是在手术前不进行激素新辅助治疗和临床定位疾病的诊断。使用这种独特的实验材料,我们分析了Affymetrix人类U133A基因芯片平台(Affymetrix,Inc.,英国海威科姆)上22,500个转录物的表达。来自具有常见管腔表型的正常/增生组织和具有基础表型(PrEC)的正常前列腺上皮组织的培养物作为对照。我们已经建立了大量高度分泌型表型的前列腺原代培养物。从他们那里,我们得到了上皮细胞限制的转录特征,其(a)将正常细胞与肿瘤细胞区分开,(b)将癌症来源的细胞清楚地分为两组,这与疾病的惰性或侵袭性临床行为有关。我们的发现提供了(a)用管腔表型扩增人原发性前列腺癌细胞的方法,(b)研究原发性前列腺癌生物学的强大实验模型,以及(c)从分子遗传学角度表征这些肿瘤的新颖方法用于预后和/或预测目的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号